---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-041199"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:25:28.547946+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio provides CFIUS update on facility sale to uBriGene; investigation due by May 13, 2024

## Summary
- Transaction involves sale of Worcester cell processing facility and manufacturing assets to uBriGene.
- CFIUS review entered a second 45-day investigation period ending May 13, 2024.
- CFIUS clearance not a condition to closing but may affect timing.

## SEC filing metadata
- accession: 0001104659-24-041199
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000110465924041199/0001104659-24-041199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000110465924041199/tm2410237d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-041199
- JSON: https://secwatch.observer/filing/0001104659-24-041199.json
- Plain text: https://secwatch.observer/filing/0001104659-24-041199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.